Stockreport

SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

Scienture Holdings, Inc.  (SCNX) 
PDF Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan mark [Read more]